Antares Pharma shares jump on upbeat PhIII results

Shares of Antares Pharma got a nice bounce after the developer touted positive late-stage data for its experimental bladder control gel therapy. And Antares says it's now on track to file an NDA for Anturol before the end of this year.

"We are delighted with the positive outcome of this Phase III trial, as both doses demonstrated a statistically significant reduction in the primary endpoint of urinary incontinence events as well as a low incidence of reported side effects," said Antares CEO Paul. K. Wotton. No data was divulged, though.

The 84 mg dose of Anturol provided statistical significant results for the secondary endpoints of urinary frequency and volume, the company added, while the 56 mg dose did not reach statistical significance. Antares shots surged 13 percent on the news.

- check out the Antares release
- here's the story from Reuters

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.